Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines
- 30 June 2009
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 45 (9), 1684-1691
- https://doi.org/10.1016/j.ejca.2009.02.022
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesotheliomaLung Cancer, 2006
- EGFR overexpression in malignant pleural mesotheliomaLung Cancer, 2006
- Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group BClinical Cancer Research, 2005
- The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050British Journal of Cancer, 2005
- Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2British Journal of Cancer, 2004
- Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR)Leukemia Research, 2003
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2002
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979